Author:
Yadav Tanuja,Mehta Velisha,Bhusare Nilam,Chintamaneni Meena,Mayur Y. C.
Publisher
Springer Nature Singapore
Reference152 articles.
1. American Cancer Society (2017) Key statistics for lung cancer. American Cancer Society, p 1–3
2. Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M (2016) MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res 21(8):1935–1943
3. Baik CS, Myall NJ, Wakelee HA (2017) Targeting BRAF -mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist 22(7):786–796
4. Bar J, Goss GD (2012) Tumor vasculature as a therapeutic target in non-small cell lung cancer. J Thorac Oncol 7(3):609–620
5. Barzi A, Pennell NA (2010) Targeting angiogenesis in non-small cell lung cancer: agents in practice and clinical development article. Eur J Clin Med Oncol 2(1):31–42